ABSTRACT Hemophilia A and B, although rare, are the most common clotting disorders in humans. With the advent of prophylaxis and improved clotting factor replacement therapy, patients with hemophilia have reached a life expectancy similar to that of the general population, leading to an increase in cardiovascular risk factors and consequently, coronary artery disease. The need for antiplatelet and anticoagulant therapy in these patients further increases the bleeding tendency. Evidence and recommendations for these patients in procedures such as percutaneous […]
